I will be present at the High content Analysis and 3D Screening Conference in Boston from Monday (November 7)  to Wednesday (November 9).

“Now in its fifteenth year, Cambridge Healthtech Institute’s High-Content Analysis & 3D Screening Conference will deliver the most recent developments in high-content and phenotypic screening. Leading pharma and academic researchers will focus on advancements in HCA technologies and applications, including screening of 3D and physiologically-relevant cellular models, data analysis techniques, and case studies and strategies for successful drug discovery. The expanded 3-day coverage on 3D cellular models and 3D screening will present the latest in spheroid, organoid and organotypic cell culture, and organ-on-a-chip technologies for drug screening, toxicity testing, and disease modeling.”

In this conference, I will present a poster on our collaborative work with Dr Karim Si-Tayeb, researcher from Institut du Thorax (CHOPIN project) on differentiation of iPS in hepatocytes in 3D culture for metabolic diseases screening.

If you want to know more on this project, don’t hesitate to come and discuss with me or contact us.

Nathalie and Julian were present during ELRIGfr event last week. They presented their company, their work and their collaborations. They have also presented two posters : the first one on a co-culture model of Parkinson and first results in 3 dimensions ; the other one on genotoxicity and steatosis assays on HepG2 cells. These next two to three months will be dedicated to validate these assays. New assays  will also be undertaken, like transporters assays, cholestasis or phospholipidosis, on HepG2 cells as well as on primary hepatotocytes. Genotoxicity assays are under validation on different cell lines as HepG2, SH-SY5Y, HeLa, HT29 cells. If you want more details, don’t hesitate to contact us.

First assays were performed these two last months on Parkinson disease cell model and we have obtained our first results on neuronal cell line culture and on co-culture of neuronal and macrophagic cells. A nice dose neurotoxicity effect was obtained with rotenone as Parkinson inducer. With these first results, we can now play with Columbus™ software to learn how it works for cell analysis.


Perkin Elmer is one of the leader in HCS equipment and furniture. To increase the quality of the results in cellular imagery, they have launched a new 384-well microplate : CellCarrier™ Ultra 384-well microplates.

We are really excited to test them!

Genetic Engineering & Biotechnology News (GEN) organise a free webinar about HCS ans HCA use in drug toxicity and genotoxicity testing.

High-content analysis (HCA) and high-content screening (HCS) enable imaging of large numbers of cellular samples for a variety of life science applications. Using automated high-resolution microscopy coupled with analytical software to visualize and quantify phenotypic responses in cells, HCS determines how compounds such as small molecule drugs, antibodies, or siRNA, affect cell morphology in a rapid, quantitative, high-throughput manner, providing meaningful functional readouts of cellular activity.

The broadcast date is Wednesday, June 11, 2014 at 10:00 am ET, 7:00 am PT, 4:00 pm CEST.

Follow this link to register : http://www.genengnews.com/webinars/high-content-screening-and-analysis-in-cell-based-assays-for-drug-toxicity-and-genotoxicity-tes/229/

“A new high-content screening software platform enables cancer researchers to uncover more about basic and advanced cellular function to accelerate cell-based research. The Thermo Scientific HCS Studio 2.0 is a high-content quantitative imaging and analysis software platform for a range of cancer research applications, including angiogenesis and migration/invasion, as well as the development of three-dimensional models of cancer stem cells and spheroid tumors. “

To know more on this information, follow this link!

%d bloggers like this: